Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is rarely recommended for unfit patients with newly diagnosed acute myeloid leukemia (AML). Patient survival can improve with venetoclax plus azacitidine (VEN plus AZA). However, the long-term outcome of this treatment strategy is still unsatisfactory. The high response and low treatment toxicity rates of patients receiving VEN plus AZA can provide an opportunity for HSCT among unfit patients. Nevertheless, the outcomes and complications of VEN plus AZA, followed by HSCT, remain unclear. Methods: This single-center retrospective study aimed to compare patients with newly diagnosed AML receiving VEN plus AZA as induction therapy (n= 27) to those receiving the conventional I3A7 regimen as induction therapy (n= 34). Result: The 1-year overall survival, relapse, and non-relapse mortality rates in the two groups were similar. The cytogenetic risks and the hematopoietic cell transplantation-specific comorbidity index are the most significant predictive factors of overall survival. Conclusion: In older patients unfit for intensive chemotherapy, a low-intensity regimen with VEN plus AZA is a suitable bridge therapy. Furthermore, allo-HSCT is feasible and can be a curative option.
背景：对于新诊断的急性髓系白血病（AML）且不适合高强度化疗的患者，通常不建议进行异基因造血干细胞移植（HSCT）。维奈托克联合阿扎胞苷（VEN联合AZA）方案可改善患者生存，但该治疗策略的长期疗效仍不理想。接受VEN联合AZA治疗的患者具有高缓解率和低治疗毒性，这为不适合高强度化疗患者接受HSCT提供了可能。然而，VEN联合AZA序贯HSCT的疗效及并发症尚不明确。方法：本单中心回顾性研究旨在比较接受VEN联合AZA诱导治疗（n=27）与接受传统I3A7方案诱导治疗（n=34）的新诊断AML患者。结果：两组患者的1年总生存率、复发率及非复发死亡率相近。细胞遗传学风险及造血干细胞移植特异性合并症指数是影响总生存的最显著预测因素。结论：对于不适合高强度化疗的老年患者，VEN联合AZA低强度方案可作为适宜的桥接治疗。此外，异基因HSCT具有可行性，可成为潜在根治性治疗选择。
肿瘤(癌症)患者之家